^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cladribine

    i
    Other names: 2-CdA, 2-Chlorodeoxyadenosine, Chlorodeoxyadenosine, Intocel, Leustatine, N-l-Leucyl-doxorubicin
    Company:
    Generic mfg.
    Drug class:
    Purinergic receptor P1 agonist
    12d
    Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (clinicaltrials.gov)
    P3, N=167, Terminated, Delta-Fly Pharma, Inc. | N=450 --> 167 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; The data met the protocol-specified criteria for futility of the investigational treatment.
    Enrollment change • Trial completion date • Trial termination
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • decitabine • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • radgocitabine (DFP-10917)
    1m
    NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)
    1m
    SZBALL01: CAV Regimen for R/R Ph- B-ALL (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • cladribine
    1m
    SZAML02: CAV Regimen for R/R AML (clinicaltrials.gov)
    P2, N=68, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • cladribine
    2ms
    Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=80, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • Vanflyta (quizartinib) • idarubicin hydrochloride • cladribine • Starasid (cytarabine ocfosfate)
    2ms
    Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases. (PubMed, Ther Adv Neurol Disord)
    The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation...However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.
    Journal
    |
    IL6R (Interleukin 6 receptor)
    |
    Rituxan (rituximab) • cyclophosphamide • methotrexate • Campath (alemtuzumab) • mitoxantrone • cladribine • Arzerra (ofatumumab) • Briumvi (ublituximab-xiiy) • fingolimod • Actemra IV (tocilizumab) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)
    3ms
    Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers (clinicaltrials.gov)
    P2, N=100, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Adverse events
    |
    cytarabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • cladribine • Starasid (cytarabine ocfosfate) • dexrazoxane
    3ms
    Erdheim-Chester Disease in Adults: 11 Cases from a Canadian Rare Diseases Program. (PubMed, Clin Hematol Int)
    Treatments included vemurafenib, interferon, tocilizumab, cladribine, cobimetinib, and cytarabine. Treatment responses varied, with several patients achieving remission or stable disease, while others had progressive or end-stage disease. This study highlights the clinical heterogeneity of ECD and the value of integrating histopathology, molecular profiling, and imaging to guide management and improve outcomes.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib) • cytarabine • Cotellic (cobimetinib) • cladribine • Actemra IV (tocilizumab)
    4ms
    RG1121403: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1/2, N=62, Recruiting, University of Washington | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    Venclexta (venetoclax) • cytarabine • mitoxantrone • cladribine • Starasid (cytarabine ocfosfate)
    4ms
    Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (clinicaltrials.gov)
    P1/2, N=84, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jun 2026
    Enrollment open • Trial initiation date
    |
    BRAF (B-raf proto-oncogene)
    |
    Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    4ms
    Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations (clinicaltrials.gov)
    P2, N=68, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • Jakafi (ruxolitinib) • cladribine • Rezlidhia (olutasidenib)